PMC4509601

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%